Irinotecano Aurovitas

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecano Aurovitas, is a topoisomerase I inhibitor presented as an injectable formulation for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer and may be considered off‑label for small cell lung cancer.

GNH USA supplies Irinotecano Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecano Aurovitas is used in colorectal cancer regimens and related oncologic pathways.

- Metastatic colorectal cancer: improves progression‑free and overall survival when combined with fluoropyrimidine‑based regimens. - Advanced colorectal cancer: incorporated into standard first‑line or second‑line chemotherapy protocols. - Small cell lung cancer (off‑label): may be considered in combination regimens for refractory disease.

Irinotecano Aurovitas may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Neutropenia - Alopecia - Fatigue - Abdominal pain

Serious or Rare Side Effects: - Severe neutropenia with fever (febrile neutropenia) - Life‑threatening diarrhea or colitis - Anaphylactic or severe allergic reactions - Hepatic toxicity (elevated transaminases) - Pulmonary toxicity (interstitial pneumonitis) - Significant electrolyte disturbances (e.g., hypokalemia).

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for toxicity.

- Dose adjustment: required for patients with hepatic impairment. - Renal function: monitor renal parameters despite primary hepatic clearance. - Myelosuppression: perform regular complete blood count monitoring. - Gastrointestinal toxicity: watch for early signs of severe diarrhea and intervene promptly. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecano Aurovitas can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce irinotecan exposure. - Concurrent use with other myelosuppressive agents: increased risk of severe neutropenia. - Live vaccines: heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate constipation. - Drugs affecting bilirubin transport (e.g., atazanavir): may increase toxicity. - Warfarin: potential for altered INR and bleeding risk.